Short Interest in Coloplast A/S (OTCMKTS:CLPBY) Drops By 26.6%

Coloplast A/S (OTCMKTS:CLPBY) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 60,200 shares, a decrease of 26.6% from the November 15th total of 82,000 shares. Based on an average trading volume of 182,400 shares, the days-to-cover ratio is presently 0.3 days.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CLPBY. UBS Group upgraded shares of Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Hsbc Global Res raised Coloplast A/S from a “moderate sell” rating to a “hold” rating in a report on Monday, November 18th.

Coloplast A/S Stock Up 1.7 %

Coloplast A/S stock traded up $0.19 during midday trading on Friday, reaching $11.68. The stock had a trading volume of 433,995 shares, compared to its average volume of 129,173. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.02 and a quick ratio of 0.56. Coloplast A/S has a twelve month low of $11.08 and a twelve month high of $14.34. The stock’s 50-day simple moving average is $12.71 and its 200 day simple moving average is $12.85.

Coloplast A/S (OTCMKTS:CLPBY) last issued its earnings results on Tuesday, November 5th. The company reported $0.08 earnings per share for the quarter. Coloplast A/S had a return on equity of 30.19% and a net margin of 18.69%. The company had revenue of $1.02 billion for the quarter. Analysts forecast that Coloplast A/S will post 0.37 earnings per share for the current fiscal year.

Coloplast A/S Increases Dividend

The firm also recently declared a dividend, which will be paid on Friday, December 20th. Shareholders of record on Monday, December 9th will be paid a $0.2435 dividend. This is a positive change from Coloplast A/S’s previous dividend of $0.05. The ex-dividend date is Monday, December 9th. Coloplast A/S’s payout ratio is presently 96.97%.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.